Efficacy and safety of benidipine therapy of essential hypertension in elderly Chinese patients.
Arzneimittelforschung
; 58(10): 505-9, 2008.
Article
in En
| MEDLINE
| ID: mdl-19025060
ABSTRACT
BACKGROUND:
Benidipine (CAS 105979-17-7) is a dihydropyridine calcium channel blocker used in the treatment of hypertension and angina pectoris.OBJECTIVE:
To examine the efficacy and safety of therapy with benidipine in elderly hypertensive patients.METHODS:
Chinese patients >60 years of age with mild to moderate essential hypertension were enrolled. The patients were prescribed benidipine at the dose of 8 mg once daily for 12 weeks. Detailed laboratory examinations and 24-h ambulatory blood pressure monitoring were performed before and after the treatment.RESULTS:
One hundred and sixty-four of the 180 patients enrolled completed the 12-week active treatment phase. Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) reductions at the end of treatment were 21.50 +/- 12.83 and 10.60 +/- 8.04 mmHg, respectively; the proportion of patients showing a good treatment response was 95.1% for SBP and 96.9% for DBP. Benidipine significantly reduced the mean 24-h ambulatory blood pressure (p < 0.001 vs. baseline) exhibiting smooth, sustained effects and high trough-to-peak ratios (T/P ratio) (0.87 for SBP and 0.72 for DBP). Moreover, benidIpine significantly reduced the systolic morning blood pressure surge and urinary albumin, and it was well tolerated. No serious adverse events were noted.CONCLUSION:
Benidipine was welltolerated and effective in elderly Chinese patients with essential hypertension.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dihydropyridines
/
Hypertension
/
Antihypertensive Agents
Type of study:
Clinical_trials
Limits:
Aged
/
Female
/
Humans
/
Male
Country/Region as subject:
Asia
Language:
En
Journal:
Arzneimittelforschung
Year:
2008
Document type:
Article